A brand launched a new pre-workout product in early 2024. The label looked clean. The manufacturer had GMP certification. The ingredients were legitimate. But eight months later, the FDA sent a warning letter — not because the product was unsafe, but because the company hadn’t submitted a New Dietary Ingredient notification for one component before going to market. The brand pulled the product, re-filed, and lost nearly a year of sales momentum.
That story is more common than most people admit. Understanding DSHEA compliance requirements is not about memorizing legal text — it’s about knowing exactly which rules apply to your product, at what point in development, and what it costs you when something falls through the cracks.
What DSHEA Actually Does — and What It Deliberately Doesn’t
The Dietary Supplement Health and Education Act of 1994 changed everything about how supplements are regulated in the United States. Before DSHEA, the FDA had wide authority to restrict supplement sales without proving a product was unsafe. After DSHEA, the burden flipped — the FDA must demonstrate that a supplement poses a significant risk to pull it from the market.
This matters deeply to manufacturers, because it means your products do not require FDA premarket approval. You don’t need to prove efficacy in clinical trials before launching. But that freedom comes with an important caveat: you are legally responsible for ensuring your products are safe, properly labeled, and manufactured to federal standards before they ever reach a retailer.
DSHEA defines a dietary supplement as a product intended to supplement the diet that contains one or more of the following: a vitamin, mineral, herb or botanical, amino acid, dietary substance to supplement the diet, or a concentrate, metabolite, constituent, extract, or combination of these. The product must be intended for ingestion and labeled as a dietary supplement. If you want a deeper look at how the dietary supplement definition shapes sourcing decisions, the regulatory framework goes further than most brands initially expect.
The FDA’s role under DSHEA is post-market. They monitor adverse event reports, conduct inspections, and can take enforcement action. But by the time the FDA gets involved, your brand’s name is already on the bottle — and on the warning letter.
The Five Label Elements You Cannot Skip
Every dietary supplement sold in the US must carry five mandatory label statements. Miss any one of them and you’re out of compliance before a single bottle is sold.
- Statement of identity: The name of the dietary supplement. It must appear on the principal display panel and clearly identify what the product is.
- Net quantity of contents: The amount of the supplement in the container — by weight, measure, or count.
- Nutrition labeling: The Supplement Facts panel, which must list serving size, servings per container, and all dietary ingredients along with their quantities and percent daily values where established.
- Ingredient list: All ingredients not listed in the Supplement Facts panel must appear in a separate ingredient list, including excipients, binders, and fillers.
- Manufacturer information: The name and place of business of the manufacturer, packer, or distributor. If the company is not the manufacturer, the label must include a phrase like “manufactured for” or “distributed by.”
The Supplement Facts panel is where most labeling errors occur. Ingredient quantities that don’t match your COA data, missing percent daily values for established nutrients, incorrect serving size declarations — these are the kinds of gaps that show up in FDA warning letters every year.
Structure/Function Claims: A Bright Line With New Flexibility in 2025
DSHEA created three categories of permissible claims for supplement labels: nutrient content claims, health claims (which require FDA authorization), and structure/function claims. For most brands, structure/function claims are the primary marketing tool — and they come with specific rules.
A structure/function claim describes the role a nutrient or ingredient plays in the body’s normal structure or function. “Supports healthy immune response.” “Promotes muscle recovery.” “Helps maintain normal blood sugar levels already within a healthy range.” These are all permissible. What you cannot say is anything that implies your product diagnoses, treats, cures, or prevents a specific disease.
“Reduces the risk of heart disease” is a disease claim, not a structure/function claim. “Supports cardiovascular health” is permissible. The line isn’t always obvious, and FDA guidance documents on structure/function claims go into considerable detail about specific claim language. When in doubt, have a regulatory consultant review your label copy before printing.
Two additional requirements attach to every structure/function claim. First, you must have substantiation — documented evidence that the claim is truthful and not misleading. Published research on the ingredient, expert opinion, or peer-reviewed studies can all serve as substantiation. Second, you must notify the FDA of the claim in writing no later than 30 days after first marketing the product.
The required disclaimer — “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” — must appear on the label and be clearly linked to each structure/function claim. In December 2025, the FDA updated its enforcement posture to no longer require this disclaimer to appear on every panel where a claim appears. The disclaimer must still be on the label; it just doesn’t need to repeat on every face of the packaging. For brands with complex multi-panel designs, this is a meaningful and cost-saving simplification.
cGMP and 21 CFR Part 111: Where Most Enforcement Actions Begin
If there is one area of DSHEA compliance requirements where brands consistently underestimate their exposure, it’s current Good Manufacturing Practice. FDA’s cGMP regulations, codified in 21 CFR Part 111, are detailed, demanding, and the source of the majority of warning letters in the supplement industry.
The regulations cover every stage of production: facility design and maintenance, personnel qualifications, equipment qualification, production and process controls, laboratory operations, and the handling and storage of finished products. They apply whether you manufacture in-house or use a contract manufacturer — and this second point is where brand owners are often caught off guard.
“If a contract manufacturer makes a mistake, FDA will blame the brand, not the contract manufacturer. The company whose name is on the bottle is responsible for ensuring that products are safe and made according to GMPs.”
— Steve Mister, President and CEO, Council for Responsible Nutrition
21 CFR Part 111 requires that every ingredient going into your product — every component — be tested or verified for identity, purity, strength, and composition. You cannot simply trust a supplier’s certificate of analysis. You are required to have documented procedures for supplier qualification, to review supplier COAs critically, and to conduct at least identity testing on incoming ingredients unless you have a qualified supplier program in place.
Batch records must be complete and traceable. Every production run needs documentation linking specific ingredient lots to finished product, along with in-process testing data and final product testing results. If you can’t trace a recall back to a specific ingredient lot and pull only affected product, your record-keeping is non-compliant regardless of whether the product itself is safe.
The five most common 21 CFR 111 violation categories in FDA inspections are: inadequate written procedures, lack of finished product specification testing, incomplete batch production records, failure to verify raw ingredient identity, and insufficient out-of-specification investigation procedures. Each is an addressable gap — but they require deliberate attention from early in your quality program design, not as a retrofit.
New Dietary Ingredients: The 75-Day Window Most Brands Don’t Know About
DSHEA established a premarket notification requirement for any dietary ingredient that was not marketed in the United States before October 15, 1994. These are called New Dietary Ingredients, or NDIs, and they represent a genuine compliance trap for product developers working with emerging or novel compounds.
If your formulation includes an NDI, the manufacturer or distributor must submit a New Dietary Ingredient Notification to the FDA at least 75 days before introducing the product to commerce. The notification must include the ingredient’s name and description, the conditions of use being recommended, safety data supporting reasonable expectation of safety, and a complete description of the manufacturing process and quality controls.
In June 2025, the FDA released new educational resources on NDI notification submissions — a signal that the agency sees widespread errors in this area and is investing in industry education rather than pure enforcement. If you’re formulating with anything that isn’t a well-established, decades-old ingredient, the NDI question must be answered explicitly before you begin manufacturing.
Standard amino acids, vitamins, and minerals that have been used in supplements for decades are almost certainly Old Dietary Ingredients with a documented pre-1994 market history. For novel compounds, exotic botanical extracts, or chemically modified forms of known ingredients, the NDI question must be answered with a regulatory attorney’s written opinion before you commit to a formulation.
Your Ingredient Supply Chain Is a Compliance Variable
Most regulatory discussions focus on what happens inside your facility or your contract manufacturer’s facility. What gets less attention is the compliance quality of the ingredient supply chain itself — and it’s where many DSHEA compliance problems actually originate.
Under 21 CFR Part 111, you are responsible for verifying that incoming ingredients meet your specifications. If a supplier ships you an ingredient that is adulterated, mislabeled, or contaminated, the FDA will hold your brand accountable for the finished product that results from it. “My supplier gave me a bad COA” is not an acceptable defense in a warning letter response.
This creates a direct link between your sourcing decisions and your regulatory posture. When you source from verified manufacturers — suppliers with documented GMP, ISO, or HACCP certifications who provide genuine specifications, proper certificates of analysis, and full regulatory documentation — you are not just making a quality decision. You are building a defensible compliance record.
Brands sourcing ingredients internationally face an additional layer of scrutiny. The FDA routinely detains imports from foreign facilities that have failed inspections or lack adequate documentation. A detained shipment doesn’t just delay your production schedule — it signals to the FDA that your supplier qualification program may need examination. The solution isn’t to avoid international sourcing. The solution is to source through partners who have already done the vetting work: who maintain relationships with GMP-certified factories, require complete documentation on every shipment, and can demonstrate the supply chain traceability that 21 CFR Part 111 demands.
For brands sourcing nutritional ingredients from China — one of the world’s deepest pools of amino acid, vitamin, and mineral manufacturing capacity — this means choosing a sourcing partner whose entire model is built around compliance documentation. Verified GMP certifications, factory audits, authentic COAs, specification sheets — these aren’t extras. They’re the foundation of a supplier qualification file that will survive an FDA audit.
A Practical DSHEA Compliance Checklist for 2025
DSHEA compliance is not a one-time project. It’s an ongoing operational discipline. Here are the key areas every supplement brand should be able to confirm at any time:
- Label review: All five mandatory label elements present; Supplement Facts panel accurate against COA data; no disease claims on label or marketing materials; structure/function disclaimer in place and linked to each claim; FDA structure/function claim notification filed within 30 days of launch
- cGMP documentation: Written master manufacturing records for every product; batch production records completed for every production run; finished product specifications defined and tested; out-of-specification investigation procedures documented
- Ingredient qualification: Supplier qualification program documented; identity testing for all incoming components; COA review procedure with clear acceptance criteria; traceability from ingredient lot to finished product
- NDI status: Each ingredient assessed for pre-1994 market history; NDI notifications submitted where required; regulatory counsel opinion on any novel compounds
- Adverse event reporting: Serious adverse event reporting procedures in place; records maintained for at least six years
Compliance officers at established brands will recognize these as standard operating territory. For emerging brands and startups, the list is a roadmap — not to fear, but to build toward systematically.
DSHEA compliance requirements are demanding precisely because supplements occupy a middle ground between food and medicine. The regulatory framework trusts you with significant commercial freedom — and asks for rigorous self-governance in return. Brands that treat compliance as a competitive advantage, rather than a cost center, tend to build the kind of operational infrastructure that scales without regulatory interruption. That starts with every ingredient in your formula. If you’d like to discuss sourcing compliant ingredients with full documentation, NutraAeon’s team responds within 48 hours.
